Specialized Alzheimer's Disease Treatment Solutions

Publication ID: 24-11857568_0009_PTD

Published: October 28, 2025

Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Alzheimer's Disease Treatment Solutions,” Published Technical Disclosure No. 24-11857568_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857568_0009_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,568.

Summary of the Inventive Concept

Adapting the original Alzheimer's disease treatment method to cater to specific, high-need populations and environments, such as high-altitude areas, regions with high air pollution, remote or disaster-stricken areas, individuals with traumatic brain injury, and high-stress occupations.

Background and Problem Solved

The original patent disclosed a method for treating mild cognitive impairment (MCI) and Alzheimer's disease using an aluminum salt. However, this method may not be effective or practical in certain environments or for specific populations. The new inventive concept addresses these limitations by adapting the original method to address the unique challenges and needs of these niche markets.

Detailed Description of the Inventive Concept

The new inventive concept comprises a system and method for treating Alzheimer's disease in high-altitude environments, preventing Alzheimer's disease in individuals living in areas with high levels of air pollution, treating Alzheimer's disease in remote or disaster-stricken areas, treating Alzheimer's disease in individuals with a history of traumatic brain injury, and preventing Alzheimer's disease in individuals working in high-stress occupations. Each of these specialized solutions incorporates the original aluminum salt-based pharmaceutical formulation, tailored to the specific needs of the target population or environment.

Novelty and Inventive Step

The new claims introduce novel and non-obvious adaptations of the original method, including the administration of the pharmaceutical formulation at high altitudes, in conjunction with air purification systems, in remote or disaster-stricken areas, in conjunction with cognitive rehabilitation programs, and in conjunction with stress management programs. These adaptations provide a unique and effective solution for specific, high-need populations and environments.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include variations in the pharmaceutical formulation, dosage, or administration schedule tailored to specific populations or environments. For example, the pharmaceutical formulation could be adapted for use in extreme weather conditions or for individuals with specific medical conditions.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in regions with high-altitude areas, air pollution, or disaster-prone areas. Additionally, the concept could be marketed to individuals working in high-stress occupations or with a history of traumatic brain injury.

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Neuropharmacology and medical treatment of cognitive disorders, specifically Alzheimer's disease and mild cognitive impairment, with expertise in pharmaceutical formulation and targeted treatment strategies

Person of Ordinary Skill (PHOSITA) Profile

A medical researcher or neuropharmacologist with advanced degree, experience in developing targeted pharmaceutical interventions, understanding of cognitive disease progression, and knowledge of environmental and physiological factors affecting neurological conditions

Obviousness Rationale

A person of ordinary skill would recognize that the source patent's aluminum salt treatment for mild cognitive impairment provides a foundational approach that can be readily adapted to specific environmental and physiological contexts. The PTD's variations represent predictable extensions of the original treatment method, applying the core pharmaceutical intervention to targeted populations with known risk factors or challenging treatment environments. These adaptations demonstrate standard scientific problem-solving by tailoring an existing treatment to address specific clinical challenges.

Obvious Combinations & Variations

Source Patent Element

Aluminum salt pharmaceutical formulation for treating mild cognitive impairment

PTD Variation

Administration of the same formulation in high-altitude environments

Obviousness Reasoning

A PHOSITA would understand that physiological changes at high altitudes might require minor dosage adjustments, but the core treatment approach remains fundamentally unchanged

Source Patent Element

Treatment method for cognitive impairment

PTD Variation

Combining pharmaceutical intervention with cognitive rehabilitation programs

Obviousness Reasoning

Integrating pharmaceutical treatment with complementary therapeutic approaches is a standard practice in neurological disorder management, representing a predictable combination of known techniques

Source Patent Element

Pharmaceutical formulation for mild cognitive impairment

PTD Variation

Adaptation for use in areas with high air pollution or extreme environmental conditions

Obviousness Reasoning

Modifying pharmaceutical delivery to account for environmental stressors is a routine approach in medical research, representing a logical extension of existing treatment strategies

Source Patent Element

Aluminum salt-based treatment for cognitive impairment

PTD Variation

Specialized administration in remote or disaster-stricken areas using portable refrigeration

Obviousness Reasoning

Developing portable medical solutions for challenging environments is a standard engineering and medical design approach, representing a predictable solution to logistical treatment challenges

Source Patent Element

Cognitive impairment treatment method

PTD Variation

Integration with stress management programs for high-stress occupational environments

Obviousness Reasoning

Recognizing and addressing environmental and occupational stress as a factor in cognitive health is a well-established medical approach, representing a logical extension of existing treatment paradigms

35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in the Published Technical Disclosure (PTD) would have been obvious to a person having ordinary skill in the art at the time of the invention, as they represent predictable extensions of the treatment methodology disclosed in US Patent 11857568. The PTD demonstrates that the core pharmaceutical intervention can be readily adapted to specific environmental and physiological contexts through routine scientific problem-solving, thereby rendering potential derivative claims obvious and non-patentable.

Original Patent Information

Patent Number	US 11,857,568
Title	Treatment and prevention of Alzheimer's disease (AD)
Assignee(s)	Advantage Therapeutics, Inc.